Meeting Banner
Abstract #4342

Imaging response to Elafibranor treatment in a rat model of non-alcoholic steatohepatitis non-invasively by oxidized-collagen molecular MRI

Veronica Clavijo Jordan 1, Iris Yuwen Zhou1, Nicholas Rotile1, Noah Warner1, Eman Aburieda Akam1, Gunisha Arora2, Smitha Krishnan2, Christian Farrar1, Alana Ross1, Bryan Fuchs2, and Peter Caravan1,3

1Athinoula A. Martinos Center for Biomedical Imaging, MGH, Harvard Medical School, Charlestown, MA, United States, 2Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, 3Institute for Innovation in Imaging (i3), Charlestown, MA, United States

Elafibranor is a dual agonist of the peroxisome proliferator-activated receptor-⍺ and δ (PPAR-⍺ and δ) in Phase III clinical trials for treatment of non-alcoholic steatohepatitis (NASH). Here, we evaluated the drug’s effectiveness in a choline-deficient high fat diet (CDAHFD) NASH model by imaging oxidized collagen as a marker for fibrogenesis in the liver using a Gd-based probe and MRI. Oxidized collagen MRI of the liver showed that Elafibranor successfully reduced fibrogenesis in rats with histologically-confirmed NASH, ex-vivo total collagen quantification by hydroxyproline assay, and histology staining, also confirmed the anti-fibrotic effect of Elafibranor in the CDAHFD-induced NASH model.

This abstract and the presentation materials are available to members only; a login is required.

Join Here